Hims & Hers Health stock price forecast: $39.50 resistance in focus as HIMS surges on Eucalyptus deal

Traders Union
All News
Financial News
Hims & Hers Health jumps 11.23% today

Highlights

Hims & Hers Health's acquisition of Eucalyptus expands its preventative healthcare reach into the UK, directly increasing its addressable market.
The deal broadens Hims & Hers Health’s international presence and intensifies investor focus on its growth and innovation in preventative care.
HIMS/USD displays strong bullish momentum with intraday overbought signals; forecast range is $31.44 to $39.50 with minimal likelihood of reversal.

International footprint expands as Eucalyptus acquisition lifts growth outlook

Hims & Hers Health has acquired Eucalyptus, the parent company of Juniper, with the transaction designed to extend its preventative healthcare services into the UK, according to Healthcaretoday. This acquisition expands Hims & Hers Health’s international footprint and unlocks access to a new patient demographic, directly increasing its addressable market. The deal has heightened investor focus on the company’s growth trajectory and innovation within the preventative care segment.

Overbought signals persist as buy momentum exceeds technical thresholds

On the technical front, HIMS trades above the MA-20 at $32.93 and the MA-50 at $30.25 on the hourly chart, as well as the MA-200 at $33.36 on the daily timeframe. The Ichimoku Kijun level at $32.36 acts as immediate support. Oscillators such as the RSI at 77, Stoch RSI, CCI, and BBP all show strong overbought readings intraday, while momentum indicators including MACD, ADX, and Awesome Oscillator maintain clear buy signals, pointing to robust and persistent upside momentum despite short-term extension risks.

Upside favored as volatility range widens with support below

Looking forward, the forecast range for HIMS over the coming days is $31.44 to $39.5, representing the expected short-term volatility band relative to current levels. The probability of continued upward movement remains very high, with a low likelihood of a reversal. The base case scenario sees price consolidating within this band; a bullish outcome would see HIMS break through resistance to extend the rally, while a bearish move could result in a pullback toward the lower end of the range should support levels not hold.

Anton Kharitonov, Analyst at Traders Union, sees the strong price action in Hims & Hers Health as primarily driven by news of the Eucalyptus acquisition and technical momentum. However, he remains cautious given the overbought signals and potential short-term extension risk. The analyst believes that consolidation within the $31.44 to $39.5 range is likely unless key support fails. "Base case is consolidation, but I would avoid chasing further upside until overbought readings reset."

Earlier, analysts noted that Hims & Hers Health was building momentum on the back of its Novo Nordisk partnership and strong technical indicators, supporting a positive outlook for the stock. The latest acquisition of Eucalyptus broadens the company's international reach and further intensifies its growth narrative, making upside volatility more likely as investor confidence builds around its expansion strategy.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.